Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BELLUS Health Inc. (T:BLU)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for BLU within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Feb 20, 2020 07:00 ET
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.
Read full article
Nov 14, 2019 07:00 ET
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ended September 30, 2019.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.09
--
--
Price to Sales - TTM
23,005.88
16.82
10.24
Price to Book - most recent quarter
6.30
3.38
2.09
Price to Cash Flow per share - TTM
--
31.32
12.33
Price to Free Cash Flow per share - TTM
--
1.27
18.32
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 31, 202029,4185,021
Jan 15, 202024,397-23,330
Dec 31, 201947,72715,797
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.

See business summary

Twitter

Search (past week) for $BLU.CA

  • No tweets found